Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Faro-Lax is a fixed-dose combination bowel preparation medication containing sodium picosulfate, magnesium oxide, and anhydrous citric acid. Developed by Faromed, it is indicated for cleansing of the colon in preparation for colonoscopy, radiography, endoscopy, or surgery in adults. Sodium picosulfate is a stimulant laxative prodrug that is hydrolyzed by colonic bacteria to its active metabolite, bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), which directly stimulates colonic peristalsis. Magnesium oxide and citric acid react in water to form magnesium citrate, an osmotic laxative that draws water into the intestinal lumen, increasing stool volume and promoting evacuation. Together, these components provide a highly effective purgative effect to clear the bowel.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on citric acid + magnesium oxide + sodium picosulfate.